查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613255

巨细胞病毒检测市场：依测试类型、样本类型、使用者群体、最终用途 – 2025-2030 年全球预测

Cytomegalovirus Tests Market by Test Type (Antigenemia Tests, Culture Tests, Molecular Tests), Sample Type (Blood Samples, Urine Samples), User Group, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

巨细胞病毒检测市场2023年估值为6.4128亿美元，预计到2024年将达到6.8078亿美元，复合年增长率为6.93%，预计到2030年将达到10.2506亿美元。

巨细胞病毒(CMV) 检测在 CMV 感染的诊断中起着至关重要的作用，特别是在免疫力缺乏的个体、新生儿和孕妇中。 CMV检测包括血清学检测、核酸增幅检查（NAAT）和抗原血症检测，每种检测都有不同的敏感性和特异性。 CMV 检测的必要性因其在预防先天性 CMV感染疾病以及移植患者和 HIV 阳性患者的管理中的重要用途而凸显，其中早期检测对于有效治疗和最大限度地减少併发症至关重要。最终用途包括医院、诊断中心和实验室。

主要市场统计
基准年[2023] 64128万美元
预测年份 [2024] 68078万美元
预测年份 [2030] 1,025,060,000 美元
复合年增长率（%） 6.93%

推动市场成长的主要因素是人们对 CMV 相关健康问题的认识不断提高、诊断技术的进步以及需要 CMV筛检的器官移植数量的增加。在意识和资源不断增加的发展中地区，存在着扩大 CMV 检测的巨大机会。此外，人工智慧和机器学习在诊断过程中的整合提供了提高准确性和效率的途径。然而，他们面临着挑战​​，包括先进检测的高成本、新兴国家缺乏认识以及血清学检测交叉反应导致的潜在不准确性。

为了充分利用市场机会，相关人员应专注于即时检测和行动装置的创新，以实现在传统实验室环境之外进行快速且易于存取的诊断。此外，对公共卫生宣传活动的投资可以提高意识并推动开拓市场的需求和扩张。提高检测灵敏度和特异性的研究和开发，特别是区分性行为感染感染和潜伏性性行为感染，是潜在成长的重要领域。儘管这是一个充满希望的市场，但仍有监管障碍和来自现有企业的竞争等挑战，需要策略定位和合作伙伴关係。 CMV 测试市场是动态的，需要技术进步和适应不断变化的医疗保健需求，以保持成长和创新。

市场动态：揭示快速发展的巨细胞病毒检测市场的关键市场洞察

供需的动态交互作用正在改变巨细胞病毒检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球 CMV感染疾病盛行率不断上升
    • 提高社会和临床对 CMV 影响的认识
    • 全球肝臟移植数量增加
  • 市场限制因素
    • 高成本且先进测试设施的使用机会有限
  • 市场机会
    • 分子诊断创新和更快、更准确测试方法的开发
    • 利用次世代定序仪和基于 CRISPR 的技术进行 CMV 检测
  • 市场挑战
    • 复杂的监管环境和特定国家的报销政策

波特的五力巨细胞病毒检测市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解巨细胞病毒检测市场的外部影响

外部宏观环境因素在塑造巨细胞病毒检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析巨细胞病毒

对巨细胞病毒测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位巨细胞病毒检测市场供应商绩效评估

FPNV定位矩阵是评估巨细胞病毒检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製巨细胞病毒检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，巨细胞病毒检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地 CMV 感染盛行率上升
      • 提高公众和临床对 CMV 影响的认识
      • 全球肝臟移植数量不断增加
    • 抑制因素
      • 成本高且先进测试设施的使用机会有限
    • 机会
      • 分子诊断创新和更快、更准确测试方法的开发
      • 使用次世代定序和基于 CRISPR 的技术进行 CMV 检测
    • 任务
      • 复杂的法规环境和特定国家的报销政策
  • 市场区隔分析
    • 测试类型：在提高分子测试（尤其是聚合酵素链锁反应）的灵敏度和特异性方面不断取得进展
    • 最终用途：研究机构更多地使用巨细胞病毒检测来开发疫苗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的巨细胞病毒测试市场

  • 抗原血症测试
  • 文化测试
  • 分子检测
  • 血清学检测

第七章依样本类型分類的巨细胞病毒检测市场

  • 血液样本
  • 尿液样本

第八章按使用者群组分類的巨细胞病毒检测市场

  • 免疫力缺乏者
  • 新生
  • 孕妇

第九章巨细胞病毒检测市场：依最终用途分类

  • 诊断实验室
  • 医院/诊所
  • 调查机构

第10章美洲巨细胞病毒检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太鉅巨细胞病毒检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲巨细胞病毒检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准扩大使用默克公司的 PREVYMIS 来预防高风险肾移植患者的 CMV
    • Diasolin 在先天性 CMV 检测方面取得突破
  • 战略分析和建议

公司名单

  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin SpA
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products BV
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market was valued at USD 641.28 million in 2023, expected to reach USD 680.78 million in 2024, and is projected to grow at a CAGR of 6.93%, to USD 1,025.06 million by 2030.

Cytomegalovirus (CMV) tests play a pivotal role in diagnosing CMV infections, particularly in immunocompromised individuals, newborns, and pregnant women. The scope of CMV testing encompasses serological assays, nucleic acid amplification tests (NAATs), and antigenemia assays, each offering varying levels of sensitivity and specificity. The necessity of CMV tests is underscored by their critical application in preventing congenital CMV infections and managing transplant recipients and HIV-positive patients, where early detection is crucial for effective treatment and minimizing complications. The end-use scope extends across hospitals, diagnostic centers, and research laboratories.

KEY MARKET STATISTICS
Base Year [2023] USD 641.28 million
Estimated Year [2024] USD 680.78 million
Forecast Year [2030] USD 1,025.06 million
CAGR (%) 6.93%

Market growth is primarily driven by increased awareness of CMV-related health issues, advancements in diagnostic technologies, and a rise in organ transplantation requiring CMV screening. Notable opportunities exist in expanding CMV testing in developing regions, where awareness and resources are growing. Furthermore, the integration of artificial intelligence and machine learning in diagnostic processes presents a pathway for enhanced accuracy and efficiency. However, the market faces challenges including high costs of advanced testing methods, insufficient awareness in emerging economies, and potential inaccuracies due to cross-reactivity in serological assays.

To capitalize on market opportunities, stakeholders should focus on innovation in point-of-care testing and portable devices, which allow for quicker, accessible diagnostics outside traditional laboratory settings. Additionally, investment in public health campaigns could elevate awareness, driving demand and expansion in untapped markets. R&D in improving the sensitivity and specificity of tests, particularly in distinguishing active from latent infections, marks a significant area of potential growth. Despite the lucrative potential, challenges such as regulatory hurdles and competition from established players necessitate strategic positioning and partnerships. The CMV tests market is dynamic, requiring adaptability to technological advancements and evolving healthcare needs to sustain growth and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cytomegalovirus Tests Market

The Cytomegalovirus Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of CMV infections across the globe
    • Growing public and clinical awareness regarding the implications of CMV
    • Increasing number of liver transplant globally
  • Market Restraints
    • High cost and limited access to sophisticated testing facilities
  • Market Opportunities
    • Innovations in molecular diagnostics and the development of faster, more accurate testing methods
    • Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
  • Market Challenges
    • Complex regulatory landscapes and varying reimbursement policies across countries

Porter's Five Forces: A Strategic Tool for Navigating the Cytomegalovirus Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cytomegalovirus Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cytomegalovirus Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cytomegalovirus Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cytomegalovirus Tests Market

A detailed market share analysis in the Cytomegalovirus Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cytomegalovirus Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cytomegalovirus Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cytomegalovirus Tests Market

A strategic analysis of the Cytomegalovirus Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Antigenemia Tests, Culture Tests, Molecular Tests, and Serological Tests.
  • Based on Sample Type, market is studied across Blood Samples and Urine Samples.
  • Based on User Group, market is studied across Immunocompromised Individuals, Newborns, and Pregnant Women.
  • Based on End Use, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CMV infections across the globe
      • 5.1.1.2. Growing public and clinical awareness regarding the implications of CMV
      • 5.1.1.3. Increasing number of liver transplant globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited access to sophisticated testing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • 5.1.3.2. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes and varying reimbursement policies across countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • 5.2.2. End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cytomegalovirus Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Antigenemia Tests
  • 6.3. Culture Tests
  • 6.4. Molecular Tests
  • 6.5. Serological Tests

7. Cytomegalovirus Tests Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Samples
  • 7.3. Urine Samples

8. Cytomegalovirus Tests Market, by User Group

  • 8.1. Introduction
  • 8.2. Immunocompromised Individuals
  • 8.3. Newborns
  • 8.4. Pregnant Women

9. Cytomegalovirus Tests Market, by End Use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Cytomegalovirus Tests Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Tests Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Tests Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
    • 13.3.2. DiaSorin's Breakthrough in Congenital CMV Detection
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbexa Ltd.
  • 2. Abbott Laboratories
  • 3. Accubiotech Co., Ltd
  • 4. AdvaCare Pharma USA
  • 5. Agilent Technologies, Inc.
  • 6. Atlas Medical GmbH
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Biogenix Inc. Pvt. Ltd.
  • 9. CLONIT srl
  • 10. Creative Diagnostics
  • 11. CTK Biotech Inc. by SSI Diagnostica A/S
  • 12. Diasorin S.p.A.
  • 13. Elabscience Bionovation Inc.
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Hangzhou Realy Tech Co., Ltd.
  • 16. Intec Products, Inc.
  • 17. IQ Products B.V.
  • 18. Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • 19. Meridian Bioscience, Inc. by SD Biosensor
  • 20. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYTOMEGALOVIRUS TESTS MARKET DYNAMICS
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 191. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023